Last reviewed · How we verify
JNJ-64232025 IV — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
JNJ-64232025 IV (JNJ-64232025 IV) — Janssen Research & Development, LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| JNJ-64232025 IV TARGET | JNJ-64232025 IV | Janssen Research & Development, LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- JNJ-64232025 IV CI watch — RSS
- JNJ-64232025 IV CI watch — Atom
- JNJ-64232025 IV CI watch — JSON
- JNJ-64232025 IV alone — RSS
Cite this brief
Drug Landscape (2026). JNJ-64232025 IV — Competitive Intelligence Brief. https://druglandscape.com/ci/jnj-64232025-iv. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab